During the past decade, UF Health Jacksonville-Gastroenterology Emerson conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 2 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UF Health Jacksonville-Gastroenterology Emerson" #1 sponsor was "Pfizer" with 3 trials, followed by "Gilead Sciences" with 2 trials sponsored, "Intercept Pharmaceuticals" with 2 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "Janssen Research & Development, LLC" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UF Health Jacksonville-Gastroenterology Emerson" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Novo Nordisk A/S" with 1 trials as a collaborator and "University of North Carolina, Chapel Hill" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "UF Health Jacksonville-Gastroenterology Emerson" are "Nonalcoholic Steatohepatitis" (3 trials), "Crohn's Disease" (2 trials), "Ulcerative Colitis" (2 trials), "Compensated Cirrhosis" (1 trials) and "HCV" (1 trials). Many other conditions were trialed in "UF Health Jacksonville-Gastroenterology Emerson" in a lesser frequency.

Most popular intervention types in "UF Health Jacksonville-Gastroenterology Emerson" are "Drug" (10 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Etrasimod" (2 trials), "Cilofexor (CILO)/Firsocostat (FIR)" (1 trials), "Deucravacitinib" (1 trials) and "Glecaprevir/Pibrentasvir (G/P) 300mg/120mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "UF Health Jacksonville-Gastroenterology Emerson" are 10 trials for "All" genders.

Currently, there are NaN active trials in "UF Health Jacksonville-Gastroenterology Emerson". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in UF Health Jacksonville-Gastroenterology Emerson, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in UF Health Jacksonville-Gastroenterology Emerson, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".